Research
December 16 2025
2025-12-16
A new study shows targeted immunotherapy halves metastasis risk in high-risk early HER2+ breast cancer
The international DESTINY-Breast05 trial, published in The New England Journal of Medicine, demonstrates that the antibody-drug conjugate trastu1